Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMHealthcare · Biotechnology
-1.61%$85.00
AH$85.00+0.00%vs close
Mkt Cap$5.52B
Float51.69M
O/S64.93M
Vol
$ Vol
RVOL
Inst Own-
SI12.9%
Earnings
Dilution
Financials Summary
Revenue$521.31M
Net Income-$23.36M
Total Assets$842.81M
Free Cash Flow$54.87M
Debt & Equity
Debt 50%
Equity 50%
Total Debt$319.45M
Total Equity$314.69M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in MIRM's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$842.81M
Liabilities$528.12M
Accounts Receivable$123.33M
Accounts Payable$9.61M
Inventory$24.89M
PP&E (Net)$10.6M
Goodwill$0
Intangible Assets$260.92M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $521.31M | $336.89M | $186.37M | $77.06M | $19.14M | $0 | $0 | $0 |
| YoY Growth | 54.7% | 80.8% | 141.8% | 302.7% | - | - | - | - |
| Cost of Revenue | $100.58M | $81.64M | $47.04M | $12.37M | $1.9M | $623K | $324K | $0 |
| Gross Profit | $420.73M | $255.25M | $139.34M | $64.69M | $17.23M | -$623K | -$324K | $0 |
| Gross Margin | 80.7% | 75.8% | 74.8% | 83.9% | 90.1% | - | - | - |
| Research and Development | $186.18M | $140.63M | $102.61M | $106.84M | $131.43M | $81.61M | $42.99M | $2.33M |
| Selling, General, and Administrative | $257.03M | $202.22M | $145.88M | $89.07M | $59.22M | $22.69M | $11.75M | $585K |
| Other | $0 | $0 | $0 | $0 | $0 | -$623K | -$21K | $0 |
| Total Operating Expenses | $443.21M | $342.85M | $248.49M | $195.91M | $190.65M | $103.67M | $54.74M | $2.92M |
| Operating Income (EBIT) | -$22.14M | -$87.61M | -$109.15M | -$131.22M | -$173.41M | -$104.3M | -$54.74M | -$2.92M |
| Operating Margin | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | - | - | - |
| Interest Expense | $14.39M | $14.31M | $15.11M | $15.98M | $17.59M | $335K | $0 | $0 |
| Interest Income | $12.73M | $13.79M | $13.73M | $3.86M | $366K | $1.56M | $2.23M | $87K |
| Other Income (Expense) | $709K | $694K | -$53.27M | -$10.85M | $89.46M | $1.03M | $2.21M | -$14.43M |
| Income Before Tax (EBT) | -$21.43M | -$86.91M | -$162.42M | -$142.07M | -$83.95M | -$103.26M | -$52.53M | -$17.35M |
| Income Tax Expense | $1.94M | $1.03M | $991K | -$6.41M | $37K | $6K | $21K | $0 |
| Net Income | -$23.36M | -$87.94M | -$163.41M | -$135.66M | -$83.99M | -$103.27M | -$52.55M | -$17.35M |
| Net Income Margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | - | - | - |
| Supplementary Data | ||||||||
| EPS | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Diluted EPS | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | -2.29 | -0.75 |
| Weighted Average OS | 50.20M | 47.52M | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
| EBITDA | $17.21M | -$48.97M | -$136.49M | -$122.85M | -$65.39M | -$102.31M | -$52.21M | -$12.96M |
| EBITDA Margin | 3.3% | -14.5% | -73.2% | -159.4% | -341.7% | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $296.68M | $222.5M | $286.33M | $28M | $31.34M | $142.09M | $11.97M | $51.96M |
| Short-Term Investments | $86.64M | $57.81M | $0 | $123.72M | $125.2M | $89.73M | $104.69M | $0 |
| Cash and Short-Term Investments | $383.33M | $280.31M | $286.33M | $151.72M | $156.54M | $231.82M | $116.66M | $51.96M |
| Accounts Receivable | $123.33M | $78.29M | $67.97M | $23.99M | $4.37M | $0 | $0 | $0 |
| Inventory | $24.89M | $22.4M | $22.31M | $5.57M | $1.51M | $0 | $0 | $0 |
| Other Current Assets | $18.14M | $11.78M | $10.94M | $8.95M | $4.17M | $0 | $0 | $12K |
| Total Current Assets | $549.68M | $392.79M | $387.54M | $190.22M | $166.59M | $236.35M | $119.36M | $51.98M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $10.6M | $9.81M | $1.99M | $2.35M | $2.55M | $3.24M | $3.73M | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $260.92M | $249.82M | $252.93M | $58.95M | $18.74M | $0 | $0 | $0 |
| Long-Term Investments | $8.11M | $12.53M | $0 | $0 | $4.98M | $0 | $23.29M | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $13.5M | $5.81M | $4.17M | $101.38M | $101.79M | $1.27M | $324K | $0 |
| Total Long-Term Assets | $293.13M | $277.97M | $259.08M | $162.68M | $128.06M | $4.51M | $27.35M | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $842.81M | $670.75M | $646.62M | $352.91M | $294.65M | $240.86M | $146.71M | $51.98M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $9.61M | $14.62M | $7.42M | $8.69M | $9.17M | $3.15M | $3.35M | $269K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $47.28M | $32.25M | $20.94M | $15.75M | $11.98M | $6.07M | $2.22M | $15K |
| Total Current Liabilities | $205.8M | $126.55M | $87.06M | $64.73M | $42.6M | $18.46M | $13.08M | $2.45M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $309.8M | $308.08M | $306.42M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $140.35M | $129.92M | $47.65M | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $5.01M | $2.51M | $3.85M | $4.53M | $17K | $29K | $36K | $59.85M |
| Total Long-Term Liabilities | $322.32M | $318.56M | $310.89M | $146.14M | $131.84M | $50.31M | $3.29M | $59.85M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $528.12M | $445.11M | $397.95M | $210.87M | $174.44M | $68.77M | $16.36M | $62.3M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $66.84M |
| Common Stock | $5K | $5K | $5K | $4K | $3K | $3K | $2K | $6.99M |
| Retained Earnings | -$667.54M | -$644.18M | -$556.24M | -$392.82M | -$257.16M | -$173.17M | -$69.9M | -$17.35M |
| Comprehensive Income & Other | $351K | -$373K | $1.64M | -$217K | -$35K | $83K | $129K | -$66.84M |
| Other Stockholders' Equity | $982.23M | $869.82M | $804.9M | $534.86M | $377.37M | $345.26M | $200.25M | $34K |
| Total Equity | $314.69M | $225.64M | $248.67M | $142.04M | $120.21M | $172.09M | $130.35M | -$10.32M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $842.81M | $670.75M | $646.62M | $352.91M | $294.65M | $240.86M | $146.71M | $51.98M |
| Supplementary Data | ||||||||
| Total Debt | $319.45M | $317.76M | $308.14M | $2.19M | $2.61M | $3.26M | $3.65M | $0 |
| Net Debt | $22.77M | $95.26M | $21.82M | -$25.82M | -$28.73M | -$138.82M | -$8.32M | -$51.96M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$23.36M | -$87.94M | -$163.41M | -$135.66M | -$83.99M | -$103.27M | -$52.55M | -$17.35M |
| Depreciation & Amortization | $24.24M | $23.63M | $10.83M | $3.24M | $975K | $623K | $324K | $4.37M |
| Deferred Income Tax | $0 | $0 | $0 | -$6.58M | $595K | $72K | $0 | $0 |
| Stock-Based Compensation | $71.42M | $48.44M | $35.02M | $27.01M | $23.09M | $12.55M | $6.07M | $51K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | -$48.05M | -$11.43M | -$43.97M | -$20.73M | $0 | $0 | $0 | $0 |
| Inventory | -$8.45M | -$3.17M | -$4.39M | -$3.45M | -$495K | $0 | $0 | $0 |
| Accounts Payable | $50.1M | $40.31M | $30.78M | $7.64M | $22.66M | $3.68M | $10.06M | $2.45M |
| Other Working Capital | -$13.31M | -$3.13M | -$5.05M | -$4.51M | -$5.18M | -$3.07M | -$2.94M | -$12K |
| Total Working Capital Change | -$19.71M | $22.59M | -$22.64M | -$21.05M | $16.98M | $611K | $7.12M | $2.44M |
| Other Non-Cash Items | $3.24M | $3.6M | $69.26M | $12.91M | -$90.41M | $335K | -$326K | $10.11M |
| Net Cash from Operating | $55.83M | $10.32M | -$70.94M | -$120.14M | -$132.76M | -$89.08M | -$39.36M | -$373K |
| Investing Activities | ||||||||
| Capital Expenditures | -$954K | -$993K | -$109K | -$278K | -$19.02M | -$225K | -$281K | -$7.5M |
| Acquisitions | $0 | $0 | -$212.76M | -$7.98M | -$19M | -$38.1M | $127.5M | $0 |
| Purchases of Investments | -$97.42M | -$89.03M | -$27.33M | -$132.32M | -$198.03M | -$74.56M | -$152M | $0 |
| Sales of Investments | $74.42M | $19.89M | $153M | $140.3M | $157.6M | $112.66M | $24.5M | $0 |
| Other Investing Activities | $0 | -$20M | -$20M | $7.98M | $127M | $38.1M | -$127.5M | -$11.25M |
| Net Cash from Investing | -$23.95M | -$90.13M | -$107.2M | $7.7M | $48.55M | $37.87M | -$127.78M | -$7.5M |
| Financing Activities | ||||||||
| Debt Repaid | - | - | -$305.3M | - | - | - | - | -$50K |
| Common Stock Issuance | $40.14M | $17.7M | $216.68M | $107.37M | $6.91M | $131.87M | $67.2M | $59.79M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | -$185.39M | $1.72M | $66.55M | $49.42M | $0 | $0 |
| Net Cash from Financing | $40.14M | $17.7M | $336.6M | $109.09M | $73.47M | $181.29M | $127.18M | $59.84M |
| Forex Effect | $3.22M | -$1.3M | -$133K | $12K | -$1K | $29K | -$27K | $0 |
| Net Change in Cash | $75.24M | -$63.4M | $158.32M | -$3.34M | -$10.75M | $130.12M | -$39.99M | $51.96M |
| Supplementary Data | ||||||||
| Operating Cash Flow | $55.83M | $10.32M | -$70.94M | -$120.14M | -$132.76M | -$89.08M | -$39.36M | -$373K |
| Capital Expenditure | -$954K | -$993K | -$20.11M | -$278K | -$19.02M | -$225K | -$281K | -$7.5M |
| Free Cash Flow | $54.87M | $9.33M | -$91.05M | -$120.41M | -$151.78M | -$89.3M | -$39.64M | -$7.87M |
| Cash at Beginning | $222.93M | $286.33M | $128M | $131.34M | $142.09M | $11.97M | $51.96M | $0 |
| Cash at End | $298.17M | $222.93M | $286.33M | $128M | $131.34M | $142.09M | $11.97M | $51.96M |